Health care biotech companies by P/B ratio
Share price divided by book value per share: what the market pays for each dollar of shareholders' equity on the balance sheet.
Biogen has the lowest figure of the 18 health care biotech companies ranked by P/B ratio, at 1.9, followed by Vaxcyte (3.5) and Neurocrine Biosciences (4.1). Figures as of 19 Nov 2026, 23:07 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 18
- Lowest
- Biogen1.9
- Median
- 8.7
- Combined market value
- CHF 699.1B
- Countries
- 5
- Not ranked
- 6no P/B ratio on file
Market values as of .
All countries▾
Health Care▾
Biotech▾
| # | Company | P/B ↑ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | BiogenBIIB · Health Care | 1.9 | CHF 30.8B | CHF 208.56 | 1.70% down | 49% up | ||
| 2 | VaxcytePCVX · Health Care | 3.5 | CHF 7.8B | CHF 49.25 | 0.27% down | 23% up | ||
| 3 | Neurocrine BiosciencesNBIX · Health Care | 4.1 | CHF 13.4B | CHF 132.15 | 3.85% down | 17% up | ||
| 4 | RepligenRGEN · Health Care | 4.6 | CHF 9.2B | CHF 143.71 | 1.38% down | 12% up | ||
| 5 | Bio-TechneTECH · Health Care | 5.3 | CHF 9.6B | CHF 61.35 | 0.07% down | 24% up | ||
| 6 | Kymera TherapeuticsKYMR · Health Care | 6.3 | CHF 8.6B | CHF 100.76 | 1.44% down | 87% up | ||
| 7 | Krystal BiotechKRYS · Health Care | 6.5 | CHF 7.9B | CHF 266.53 | 0.15% up | 54% up | ||
| 8 | CG OncologyCGON · Health Care | 7.4 | CHF 6.2B | CHF 69.12 | 2.38% up | 97% up | ||
| 9 | Twist BioscienceTWST · Health Care | 8.5 | CHF 6.4B | CHF 94.20 | 4.07% down | 346% up | ||
| 10 | ExelixisEXEL · Health Care | 8.8 | CHF 13.6B | CHF 55.56 | 3.60% down | 63% up | ||
| 11 | ImmunovantIMVT · Health Care | 10.2 | CHF 5.7B | CHF 27.44 | 1.96% down | 46% up | ||
| 12 | ModernaMRNA · Health Care | 11.8 | CHF 68.1B | CHF 168.22 | 1.29% up | 780% up | ||
| 13 | Revolution MedicinesRVMD · Health Care | 14.4 | CHF 29.1B | CHF 134.55 | 0.24% down | 129% up | ||
| 14 | Gilead SciencesGILD · Health Care | 15.8 | CHF 174.3B | CHF 140.54 | 1.45% down | 35% up | ||
| 15 | AmgenAMGN · Health Care | 16.5 | CHF 200.3B | CHF 370.34 | 1.14% down | 32% up | ||
| 16 | Adaptive BiotechnologiesADPT · Health Care | 25.7 | CHF 3.8B | CHF 23.67 | 1.44% down | 74% up | ||
| 17 | Scholar Rock HoldingSRRK · Health Care | 36.4 | CHF 5.2B | CHF 42.51 | 4.94% up | 26% up | ||
| 18 | Kodiak SciencesKOD · Health Care | 499 | CHF 5.4B | CHF 82.62 | 0.09% up | 399% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Sums are converted from US dollars at today's exchange rate (1 USD = 0.8439 CHF). 6 companies have no P/B ratio on file and are not ranked here.
Questions and answers
Which health care biotech companies have the lowest P/B ratio?
Biogen (1.9), Vaxcyte (3.5) and Neurocrine Biosciences (4.1) have the lowest P/B ratio of the 18 health care biotech companies ranked here as of 19 Nov 2026, 23:07 UTC.
How many health care biotech companies are in this ranking?
18 are ranked by P/B ratio. 6 more have no P/B ratio on file and are left out rather than ranked at zero.
What are these health care biotech companies worth together?
The 18 health care biotech companies ranked by P/B ratio have a combined market value of CHF 699.1B as of 19 Nov 2026, 23:07 UTC.
What does ranking by P/B ratio measure?
Share price divided by book value per share: what the market pays for each dollar of shareholders' equity on the balance sheet.
Learn how this ranking works
All markets guides →- P/E ratio explained: what a high or low figure means
The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- Piotroski F-score: the nine tests and what they show
The Piotroski F-score is a 0–9 count of simple accounting tests a company passes: four on profitability, three on debt, liquidity and share issuance, two on operating efficiency. Joseph Piotroski's 2000 paper found that among cheap, high book-to-market stocks, high scorers went on to beat low scorers. It is a screen of financial health, not a valuation.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Health care biotech companies by P/B ratio”, data as of 19 November 2026. https://funkfolio.com/companies/category/biotech?sector=health-care&by=pb-ratio
Underlying data: Yahoo Finance; SEC EDGAR.